121 results about "Metabolic Marker" patented technology

The invention discloses a metabolic marker combination for evaluating the risks of cardiovascular and cerebrovascular disease of a subject. The metabolic marker combination comprises ceramide Cer d18:1 / 16:0, ceramide Cer d18:1 / 18:0, ceramide Cer d18:1 / 24:0, phenylacetyl glutamine, trimethylamine, glycine betaine and choline. The cardiovascular and cerebrovascular diseases are selected from coronary heart disease, atherosclerosis, atrial fibrillation and heart failure. The metabolic marker combination disclosed by the invention has the advantages of high sensitivity, good specificity, quantification, high detection flux and the like in the aspect of evaluating or predicting the risks of cardiovascular and cerebrovascular diseases.

The invention discloses a serum metabolic marker for tuberculosis drug resistance diagnosis and application thereof. The serum metabolite is selected from at least one of 30 serum metabolite such as stearoyl glutamic acid; analysis is performed according to the serum metabolite of individuals with different tuberculosis drug resistance types; and a novel thought is provided for tuberculosis drug resistance diagnosis from the perspective of the serum metabolite.

The invention belongs to the technical field of clinical medical diagnosis and relates to a screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis. The screening method of the early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis liver cirrhosis and hepatitis comprises the following steps of: S1, acquiring data, specifically, collecting a target plasma sample and detecting metabolites in the plasma sample; S2, constructing a discrimination model used for distinguishing people with liver cirrhosis from patients with the primary liver cancer and distinguishing people with the hepatitis from patients with the primary liver cancer; S3, screening markers; and S4, verifying diagnosis capability. According to the screening method of early-stage liver cancer diagnosis markers for people with liver cirrhosis and hepatitis, a high performance liquid chromatography-mass spectrometry system is utilized to obtain the metabolic profiles of blood plasma of patients with liver cirrhosis, hepatitis and hepatocellular carcinoma, a potential tumor metabolic marker group is found, and a diagnosis model is constructed and is used for assisting early diagnosis of tumors of groups with high risk of liver cancer.

The present invention belongs to the technical field of screening and identification of nephrotic syndrome markers, and provides nephrotic syndrome progression-related metabolic markers and application thereof. Bis(4-ethylbenzyl)sorbitol, C16 d-sphinganine, lysophosphatidylethanolamine (LPE) (22:6), lysophosphatidylcholine (LPC) (22:5), N-ethanolamine and proline are taken as progressive markers; oleic acid amide, docosahexaenoic acid, 14S-hydroxy-docosahexaenoic acid, docosapentaenoic acid, uric acid, and LPC (20:5) and (18:1) are taken as early markers; and acylcarnitine (C18:0), linoleic acid carnitine, LPC (18:3), DL-tryptophan, indoleacrylic acid, p-cresol sulfate, 3-indol sulfate, cytosine, creatinine, sphingosine-1-phosphoric acid, L-aleuritic-dihydrosphingosine and ceramide (d18:0 / 14:0) are taken as late markers. The nephrotic syndrome progression-related metabolic markers provided by the present invention can be quantified, are fast, and have high sensitivity and strong specificity.

Methods for monitoring the immune response and predicting clinical outcomes for patients on immunosuppressive drugs (such as transplant patients) are provided. The methods are based on the measurement of an intracellular metabolic marker in lymphocytes (such as ATP) as an indicator of a patient's immune response.

The invention provides a metabolic marker for diagnosing or monitoring lung adenocarcinoma and a screening method and application of the metabolic marker. A metabolic marker system is selected from one or a combination of more of D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine and kynuric acid. The metabolic marker provided by the invention can accurately diagnose a lung adenocarcinoma patient, can distinguish an early-stage lung adenocarcinoma patient from a healthy person, is high in sensitivity and strong in specificity, can well replace an existing tissue biopsy and imaging diagnosis mode, and reduces trauma and radiation risks.

The invention relates to a method for detecting small-molecule metabolic markers in the peripheral blood of aortic dissection, and its application. Combined chromatography and mass spectrometry are employed for high-flux large-scale metabonomic analysis of patients with aortic dissection to determine small-molecule metabolic profiling of the peripheral blood of the aortic dissection, and three small-molecule metabolic markers with greatest difference is obtained, wherein the three small-molecule metabolic markers are N1-acetyl-N2-formyl-5-methoxy kynurenine, glycerophosphorylcholine and 2-mercaptohistidine betaine. The invention provides a simple, low-harm and cheap method for screening and diagnosis of aortic dissection, and effective reference bases can be provided for diagnosis of clinical patients and assessment of the treatment efficacy of drugs.

The invention discloses an application of a metabolic marker in atherosclerotic cerebral infarction, which comprises the following steps: collecting blood samples of atherosclerotic cerebral infarction and atherosclerotic patients, carrying out metabonomics analysis, and discovering metabolites with significant differences in two groups, therefore, the metabolite is utilized to predict early atherosclerotic cerebral infarction, and early treatment of a patient is further realized.

The invention discloses a method for identifying metabolic markers based on heart Yang deficiency syndrome of coronary heart diseases. The method solves the problem that the existing clinical diagnosis method of heart Yang deficiency syndrome of coronary heart diseases has poor sensitivity so that the relationship between ingredients in the formula and curative effects is difficult to recover. Themethod comprises 1, carrying out UPLC analysis on n healthy subjects and n patient subjects suffering from heart Yang deficiency syndrome of coronary heart diseases through a UPLC-G2-Si-HDMS method to determine endogenous metabolites in serum samples, 2, carrying out full scanning on the endogenous metabolites in a positive and negative ion mode through a G2-Si-HDMS method to determine endogenousmetabolite structures and 3, identifying blood metabolic biomarkers of subjects suffering from heart Yang deficiency syndrome of coronary heart diseases. The method is used in the field of metabolicmarker identification.